search
Back to results

Sleep Modulation as Antidepressant Randomized Trial (SMART)

Primary Purpose

Depression, Healthy

Status
Recruiting
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Phase-targeted auditory stimulation
Sponsored by
Giulia Da Poian
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Depression focused on measuring Healthy, Depression, Auditory stimulation, Sleep

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Male and female adults aged 18-55 years Motivated, no aversion against technology Able to give informed consent as documented by signature, and to follow the technical instructions Able to understand and speak German or English as required for the interview (HDRS) and to answer the questionnaires Diagnosis of depression according to DSM-5 criteria (depressed) OR no diagnosis of depression AND no depressive episode in the history (healthy) ≥17 points in Hamilton Depression Rating Score (HDRS, corresponding to at least moderate-mild depression, depressed) OR <8 points in HDRS (healthy) Stable or no pharmacological antidepressant therapy, no acute suicidal tendency (depressed) Exclusion Criteria: Pregnant or lactating women, women planning to get pregnant during the study period Bipolar disorder or psychotic symptoms in the history Relevant disease or medication that could present a risk for the participant or that could influence study findings Known sleep apnea (diagnosed or ESS ≥10 points) or periodic limb movement syndrome Known alcoholism or drug abuse Diagnosed hearing impairment/presbycusis Irregular intake of centrally depressing or stimulating medication known to alter sleep EEG (e.g., benzodiazepines) History of traumatic brain injury (except for concussion) or neurosurgical procedures/operations Known epilepsy or for any reason, intracranial space-occupying lesions or (infectious or autoimmune) inflammatory diseases of the central nervous system Shift workers Inability to follow the procedures of the study, e.g., due to language problems, dementia, etc. Skin diseases/skin problems (in the face/ear/chest area) or allergies that could be aggravated by electrode application Conditions that may interfere with the MRI (e.g., MR unsafe cardiac pacemaker or a defibrillator, MR unsafe metal in or near the head, spinal cord, eyes, or in the chest) Indications of sleep apnea (Apnea Hypopnea Index >15/h) or periodic limb movement syndrome (PLMS index >15/h) in the screening night Low stimulation efficiency (<500 stimulations detected by the device) in the screening night or in 3 subsequent home recording nights, e.g., due to very little deep sleep Participation in another clinical trial during the study period

Sites / Locations

  • Sensory-Motor Systems LabRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Auditory stimulation first

Sham stimulation first

Arm Description

This study group receives auditory stimulation in the first intervention week (second week of trial) and sham stimulation in the second intervention week (fourth week of trial).

This study group receives sham stimulation in the first intervention week (second week of trial) and auditory stimulation in the second intervention week (fourth week of trial).

Outcomes

Primary Outcome Measures

Depression severity
Change in Hamilton Depression Rating Score (HDRS) as compared to baseline score. The 17-item HDRS is on a scale of 0-52 with higher scores indicating more severe symptomatology.

Secondary Outcome Measures

Response rate
Change in response rate in the Hamilton Depression Rating Score. Response is defined as a reduction of at least 50% compared to baseline or score <8 points.
Subjective momentary sleepiness
Compare momentary sleepiness using the Karolinska Sleepiness Scale (KSS) between the two intervention weeks. KSS scores range from 1-10 with higher scores indicating higher sleepiness.
Electroencephalographic (EEG) topography
Change in topography of the electric brain activity (EEG) during sham and stimulation night in the laboratory. Spectral decomposition of the signal will be performed to compare single frequency bins and established frequency bands (delta, theta, alpha, sigma, beta, gamma).
MR Spectroscopy
Changes in Glutamate/Glutamine (combined as Glx) in the dorsolateral prefrontal cortex as assessed by magnetic resonance spectroscopy between sham and stimulation weeks.
Brain connectivity
Change in resting state functional connectivity (fMRI) between sham and stimulation weeks.

Full Information

First Posted
January 3, 2023
Last Updated
March 15, 2023
Sponsor
Giulia Da Poian
Collaborators
ETH Zurich, University of Zurich, Psychiatric University Hospital, Zurich
search

1. Study Identification

Unique Protocol Identification Number
NCT05685771
Brief Title
Sleep Modulation as Antidepressant Randomized Trial
Acronym
SMART
Official Title
Assessing the Symptomatic Benefit of Slow-wave Activity Reduction Using Wearables and Sensor-based Characterization of Depression: a Randomized, Counter-balanced Crossover Study
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 20, 2023 (Actual)
Primary Completion Date
June 30, 2024 (Anticipated)
Study Completion Date
June 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Giulia Da Poian
Collaborators
ETH Zurich, University of Zurich, Psychiatric University Hospital, Zurich

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The goal of this clinical trial is to learn about the effects of phase-targeted auditory stimulation in depressed patients and healthy controls. The main questions it aims to answer are: Is auditory down-phase stimulation efficient in improving depression symptoms as compared to sham stimulation? Can mood and other outcomes be prospectively estimated by multi-parametric passive data? Participants will perform auditory stimulation using a wearable device at home and provide data on their phone usage and activity. Researchers will compare depressed patients and healthy participants to see if auditory down-phase stimulation effects them differently.
Detailed Description
This study consists of two parts: CLINICAL TRIAL PART: This part will be conducted in depressed and age- and sex-matched healthy participants. It has a double-blind, randomized crossover design. Each participant will undergo 1 week of baseline monitoring, followed by 1 week of in-home stimulation and 1 week of placebo condition interleaved with 1 week wash-out period. The last night of each intervention week will take place in a laboratory setting. A final week of follow-up will follow the second intervention week. The following data is collected: Single-channel EEG (at home) and high-density electroencephalogram (hdEEG) (in laboratory) MR imaging Daily questionnaires Passive behavioural and physiological measurements MONITORING PART: This observational study part will be conducted in depressed participants only. Each participant will undergo 5 weeks of remote monitoring using wearable devices and smartphones. Patients not eligible for the CLINICAL TRIAL PART, or that meet an exclusion criterion at any point in the study, can be assigned to this study part.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depression, Healthy
Keywords
Healthy, Depression, Auditory stimulation, Sleep

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Auditory stimulation first
Arm Type
Other
Arm Description
This study group receives auditory stimulation in the first intervention week (second week of trial) and sham stimulation in the second intervention week (fourth week of trial).
Arm Title
Sham stimulation first
Arm Type
Other
Arm Description
This study group receives sham stimulation in the first intervention week (second week of trial) and auditory stimulation in the second intervention week (fourth week of trial).
Intervention Type
Device
Intervention Name(s)
Phase-targeted auditory stimulation
Intervention Description
Bursts of pink noise (50 ms) played during deep non-REM sleep at specific phases of sleep slow waves.
Primary Outcome Measure Information:
Title
Depression severity
Description
Change in Hamilton Depression Rating Score (HDRS) as compared to baseline score. The 17-item HDRS is on a scale of 0-52 with higher scores indicating more severe symptomatology.
Time Frame
baseline; after first intervention week; after second intervention week
Secondary Outcome Measure Information:
Title
Response rate
Description
Change in response rate in the Hamilton Depression Rating Score. Response is defined as a reduction of at least 50% compared to baseline or score <8 points.
Time Frame
after first intervention week; after second intervention week
Title
Subjective momentary sleepiness
Description
Compare momentary sleepiness using the Karolinska Sleepiness Scale (KSS) between the two intervention weeks. KSS scores range from 1-10 with higher scores indicating higher sleepiness.
Time Frame
first intervention week; second intervention week
Title
Electroencephalographic (EEG) topography
Description
Change in topography of the electric brain activity (EEG) during sham and stimulation night in the laboratory. Spectral decomposition of the signal will be performed to compare single frequency bins and established frequency bands (delta, theta, alpha, sigma, beta, gamma).
Time Frame
last night of first intervention week; last night of second intervention week
Title
MR Spectroscopy
Description
Changes in Glutamate/Glutamine (combined as Glx) in the dorsolateral prefrontal cortex as assessed by magnetic resonance spectroscopy between sham and stimulation weeks.
Time Frame
after first intervention week; after second intervention week
Title
Brain connectivity
Description
Change in resting state functional connectivity (fMRI) between sham and stimulation weeks.
Time Frame
after first intervention week; after second intervention week

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Male and female adults aged 18-55 years Motivated, no aversion against technology Able to give informed consent as documented by signature, and to follow the technical instructions Able to understand and speak German or English as required for the interview (HDRS) and to answer the questionnaires Diagnosis of depression according to DSM-5 criteria (depressed) OR no diagnosis of depression AND no depressive episode in the history (healthy) ≥17 points in Hamilton Depression Rating Score (HDRS, corresponding to at least moderate-mild depression, depressed) OR <8 points in HDRS (healthy) Stable or no pharmacological antidepressant therapy, no acute suicidal tendency (depressed) Exclusion Criteria: Pregnant or lactating women, women planning to get pregnant during the study period Bipolar disorder or psychotic symptoms in the history Relevant disease or medication that could present a risk for the participant or that could influence study findings Known sleep apnea (diagnosed or ESS ≥10 points) or periodic limb movement syndrome Known alcoholism or drug abuse Diagnosed hearing impairment/presbycusis Irregular intake of centrally depressing or stimulating medication known to alter sleep EEG (e.g., benzodiazepines) History of traumatic brain injury (except for concussion) or neurosurgical procedures/operations Known epilepsy or for any reason, intracranial space-occupying lesions or (infectious or autoimmune) inflammatory diseases of the central nervous system Shift workers Inability to follow the procedures of the study, e.g., due to language problems, dementia, etc. Skin diseases/skin problems (in the face/ear/chest area) or allergies that could be aggravated by electrode application Conditions that may interfere with the MRI (e.g., MR unsafe cardiac pacemaker or a defibrillator, MR unsafe metal in or near the head, spinal cord, eyes, or in the chest) Indications of sleep apnea (Apnea Hypopnea Index >15/h) or periodic limb movement syndrome (PLMS index >15/h) in the screening night Low stimulation efficiency (<500 stimulations detected by the device) in the screening night or in 3 subsequent home recording nights, e.g., due to very little deep sleep Participation in another clinical trial during the study period
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Giulia Da Poian, PhD
Phone
0446325795
Ext
+41
Email
giulia.dapoian@hest.ethz.ch
First Name & Middle Initial & Last Name or Official Title & Degree
Corinne Eicher, MSc
Phone
0792609279
Ext
+41
Email
corinne.eicher@pukzh.ch
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Giulia Da Poian, PhD
Organizational Affiliation
Sensory-Motor Systems Lab, IRIS, ETH Zurich
Official's Role
Principal Investigator
Facility Information:
Facility Name
Sensory-Motor Systems Lab
City
Zurich
ZIP/Postal Code
8092
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Giulia Da Poian, PhD
Phone
0446325795
Ext
+41
Email
giulia.dapoian@hest.ethz.ch
First Name & Middle Initial & Last Name & Degree
Cristina Gallego Vázquez, MSc
Phone
0446325630
Ext
+41
Email
cristina.gallegovazquez@hest.eth.ch

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Data obtained through this study may be provided to qualified researchers with academic interest in sleep research and depression. Data or samples shared will be coded, with no PHI included. Approval of the request and execution of all applicable agreements (i.e. a material transfer agreement) are prerequisites to the sharing of data with the requesting party.
IPD Sharing Time Frame
Data requests can be submitted starting after article publication
IPD Sharing Access Criteria
Access to trial IPD can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and execution of a Data Sharing Agreement (DSA)

Learn more about this trial

Sleep Modulation as Antidepressant Randomized Trial

We'll reach out to this number within 24 hrs